Here we report that FGF15/19 represses hepatic lipogenesis by activating SHP and DNMT3A physiologically, but this regulation is defective in obese mice and possibly in NAFLD patients. This evidence concerns the gene DNMT3A and metabolic dysfunction-associated steatotic liver disease.